Share your information on an upcoming Stock Catalyst. Please provide details (Catalyst type, and Link to information) and why you think it’s a catalyst. Sharing information is what helps us all grow, Thank you!

The more information provided, the better everyone can make a decision on the value of the information, and plan a trade.

Once you submit the information we will evaluate shortly. Thank you!

Some great catalyst are Biotechs with upcoming PDUFA dates, Clinical studies results, and Earnings reports.

Plenty of times a stock price will move into an upcoming catalyst, and provide for a great trading opportunity.

 
 

These events/catalyst/information is not verified or confirmed, nor are there any promises of accuracy. Please do your own due diligence prior to making any financial decision.

 
 


Sun Mon Tue Wed Thu Fri Sat
1
ALT Biotech Catalyst 8:00 am
ALT Biotech Catalyst
Jul 1 @ 8:00 am – Sep 30 @ 2:00 pm
ALT Biotech Catalyst
ALT – Altimmune, Inc. has three upcoming catalyst. 2 catalyst in 3Q and 1 in 4Q of 2018, and plenty of insider buying. #ALT NASOSHIELD, Anthrax vaccine – has Phase 1 data due early 3Q[...]
SELB – Selecta Biosciences, SEL-212 Data 11:14 am
SELB – Selecta Biosciences, SEL-212 Data
Sep 1 @ 11:14 am – Sep 30 @ 12:14 pm
SELB - Selecta Biosciences, SEL-212 Data
SELB – Selecta Biosciences, is due to present data from patients receiving five monthly doses of SEL-212, expected to be presented at Q3 medical conferenceSEL-212 (Most likely in September). https://stocksnewsfeed.com/selecta-biosciences-presents-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-chronic-severe-gout-at-eular-2018/ Since we still have a[...]
2
3
AVEO Pharmaceuticals Phase 3 top-line data TIVO-3 – tivozanib 6:48 pm
AVEO Pharmaceuticals Phase 3 top-line data TIVO-3 – tivozanib
Sep 3 2018 @ 6:48 pm – Feb 2 2019 @ 7:48 pm
AVEO Pharmaceuticals Phase 3 top-line data TIVO-3 - tivozanib
AVEO Pharmaceuticals has Phase 3 top-line data for it’s TIVO-3 in the 4th Quarter of 2018. TIVO-3 is designed to support regulatory approval of tivozanib in the U.S. as a first- and third-line treatment for[...]
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30